FOCUS: Ranibizumab + Verteporfin PDT in Neovascular AMD

Phase 2, randomised, single-blind trial of ranibizumab in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Genentech. Primary endpoints: Proportion of patients who lost fewer than 15 letters of visual acuity at 12 months and Incidence of ocular and systemic adverse events at 24 months. Started Mar 2003; status: completed.